OCU400's Phase 3 readout in retinitis pigmentosa will determine whether Ocugen's gene-agnostic approach can convert 3-year durability signals into registrational proof

Bull

A positive readout would show statistically significant improvement in low luminance visual acuity (LLVA) or a pre-specified functional endpoint across both the RHO-specific and gene-agnostic arms, with the ~2-line gain seen in Phase 1/2 reproduced at scale across 25+ mutations in 140 patients. This would validate OCU400 as the first broadly applicable gene therapy for RP regardless of genotype, differentiate it from single-mutation approaches, and support rolling BLA submission — unlocking the full addressable RP population and substantially de-risking the licensing deal with Kwangdong Pharmaceutical.

Bear

The most likely failure mode is that the gene-agnostic benefit observed in a small, selected Phase 1/2 cohort does not replicate in a larger, more heterogeneous Phase 3 population — particularly if efficacy is diluted across rarer or more advanced-mutation subgroups where baseline visual function is too compromised to show improvement. A second risk is endpoint selection: if the FDA-agreed primary endpoint proves insufficiently sensitive to capture the modest functional gains seen in Phase 1/2, the trial could miss statistical significance even with a biologically real signal, stalling the BLA and forcing a redesign.